Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):800–804. doi: 10.1038/bjc.1992.363

Treatment with a non-steroidal anti-inflammatory agent delays the growth of spontaneous pulmonary metastases of a mammary adenocarcinoma of non-detected immunogenicity.

P A Fontán 1, C R Amura 1, D O Sordelli 1
PMCID: PMC1977982  PMID: 1419623

Abstract

Previous reports showed that treatment with non-steroidal anti-inflammatory agents (NSAIA) can alter the growth profile of a variety of tumours. In this study, the effect of NSAIA treatment on the growth of the primary tumour and the appearance of spontaneous pulmonary metastases, was investigated. A mammary adenocarcinoma of non-detected immunogenicity, C7HI, was grafted subcutaneously in the lateral flank of Balb/c mice. Oral treatment with approximately 1 mg kg-1 day-1 piroxicam delayed both tumour growth and the growth of pulmonary metastases. Survival of mice bearing the primary tumour was significantly lengthened by anti-inflammatory treatment. Similarly, in separate experiments, after surgical removal of the primary tumour by day 34 after grafting, the group of mice treated orally with piroxicam also exhibited a higher survival rate than the control group. Upon surgical removal of the primary tumour 34 days after grafting, piroxicam treatment significantly decreased both the number and size of pulmonary metastases. The results of this study lends support to the hypothesis that inhibition or modulation of inflammation may delay tumour organisation and growth. It is suggested that piroxicam treatment may be an appropriate adjunct therapy to delay the appearance of pulmonary metastases and to increase life-expectancy in a host whose primary tumour has to be surgically removed.

Full text

PDF
800

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aeed P. A., Nakajima M., Welch D. R. The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. Int J Cancer. 1988 Nov 15;42(5):748–759. doi: 10.1002/ijc.2910420521. [DOI] [PubMed] [Google Scholar]
  2. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  3. Boutwell R. K. Diet and anticarcinogenesis in the mouse skin two-stage model. Cancer Res. 1983 May;43(5 Suppl):2465s–2468s. [PubMed] [Google Scholar]
  4. Fisher B., Saffer E., Rudock C., Coyle J., Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 1989 Apr 15;49(8):2002–2004. [PubMed] [Google Scholar]
  5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  6. Fu Y. X., Cai J. P., Chin Y. H., Watson G. A., Lopez D. M. Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSF. Int J Cancer. 1992 Feb 20;50(4):585–588. doi: 10.1002/ijc.2910500416. [DOI] [PubMed] [Google Scholar]
  7. Fulton A. M., Zhang S. Z., Chong Y. C. Role of the prostaglandin E2 receptor in mammary tumor metastasis. Cancer Res. 1991 Apr 15;51(8):2047–2050. [PubMed] [Google Scholar]
  8. Gelin J., Andersson C., Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 1991 Feb 1;51(3):880–885. [PubMed] [Google Scholar]
  9. Goodwin J. S. Immunologic effects of nonsteroidal anti-inflammatory agents. Med Clin North Am. 1985 Jul;69(4):793–804. doi: 10.1016/s0025-7125(16)31019-7. [DOI] [PubMed] [Google Scholar]
  10. Hirsch B., Johnson J. T., Rabin B. S., Thearle P. B. Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences. Arch Otolaryngol. 1983 May;109(5):298–301. doi: 10.1001/archotol.1983.00800190020005. [DOI] [PubMed] [Google Scholar]
  11. Killion J. J., Fidler I. J. The biology of tumor metastasis. Semin Oncol. 1989 Apr;16(2):106–115. [PubMed] [Google Scholar]
  12. Kort W. J., Hulsman L. O., van Schalkwijk W. P., Weijma I. M., Zondervan P. E., Westbroek D. L. Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. J Natl Cancer Inst. 1986 Apr;76(4):711–720. doi: 10.1093/jnci/76.4.711. [DOI] [PubMed] [Google Scholar]
  13. Lau S. S., McMahon J. B., McMenamin M. G., Schuller H. M., Boyd M. R. Metabolism of arachidonic acid in human lung cancer cell lines. Cancer Res. 1987 Jul 15;47(14):3757–3762. [PubMed] [Google Scholar]
  14. Lichtenstein A. Stimulation of the respiratory burst of murine peritoneal inflammatory neutrophils by conjugation with tumor cells. Cancer Res. 1987 May 1;47(9):2211–2217. [PubMed] [Google Scholar]
  15. Liotta L. A. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986 Jan;46(1):1–7. [PubMed] [Google Scholar]
  16. Milas L., Furuta Y., Hunter N., Nishiguchi I., Runkel S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res. 1990 Aug 1;50(15):4473–4477. [PubMed] [Google Scholar]
  17. Orr F. W., Warner D. J. Effects of neutrophil-mediated pulmonary endothelial injury on the localization and metastasis of circulating Walker carcinosarcoma cells. Invasion Metastasis. 1987;7(3):183–196. [PubMed] [Google Scholar]
  18. Otterness I. G., Larson D. L., Lombardino J. G. An analysis of piroxicam in rodent models of arthritis. Agents Actions. 1982 Jul;12(3):308–312. doi: 10.1007/BF01965395. [DOI] [PubMed] [Google Scholar]
  19. Panje W. R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 1981 Nov;107(11):658–663. doi: 10.1001/archotol.1981.00790470006003. [DOI] [PubMed] [Google Scholar]
  20. Pollard M., Luckert P. H. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res. 1989 Dec 1;49(23):6471–6473. [PubMed] [Google Scholar]
  21. Prehn R. T. The inhibition of tumor growth by tumor mass. Cancer Res. 1991 Jan 1;51(1):2–4. [PubMed] [Google Scholar]
  22. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
  23. Sordelli D. O., Cerquetti M. C., Fontán P. A., Meiss R. P. Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa. J Infect Dis. 1989 Feb;159(2):232–238. doi: 10.1093/infdis/159.2.232. [DOI] [PubMed] [Google Scholar]
  24. Sordelli D. O., Fontán P. A., Meiss R. P., Ruggiero R. A., Bustuoabad O. D. Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity. Br J Cancer. 1989 Nov;60(5):734–738. doi: 10.1038/bjc.1989.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tsunamoto K., Todo S., Imashuku S. Effects of 5-bromo-2'-deoxyuridine on arachidonic acid metabolism of neuroblastoma and leukemia cells in culture: a possible role of endogenous prostaglandins in tumor cell proliferation and differentiation. Prostaglandins Leukot Med. 1987 Feb;26(2):157–169. doi: 10.1016/0262-1746(87)90110-7. [DOI] [PubMed] [Google Scholar]
  26. Utsugi T., Fidler I. J. Prostaglandin E2 does not inhibit tumoricidal activity of mouse macrophages against adherent tumor cells. J Immunol. 1991 Mar 15;146(6):2066–2071. [PubMed] [Google Scholar]
  27. Vanderveen E. E., Grekin R. C., Swanson N. A., Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol. 1986 Apr;122(4):407–412. doi: 10.1001/archderm.122.4.407. [DOI] [PubMed] [Google Scholar]
  28. Verma A. K., Ashendel C. L., Boutwell R. K. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1980 Feb;40(2):308–315. [PubMed] [Google Scholar]
  29. Young M. R., Newby M. Enhancement of Lewis lung carcinoma cell migration by prostaglandin E2 produced by macrophages. Cancer Res. 1986 Jan;46(1):160–164. [PubMed] [Google Scholar]
  30. Young M. R., Young M. E., Wepsic H. T. Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive metastatic Lewis lung carcinoma cells. Cancer Res. 1987 Jul 15;47(14):3679–3683. [PubMed] [Google Scholar]
  31. el Attar T. M., Lin H. S. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs. J Oral Pathol. 1987 Nov;16(10):483–487. doi: 10.1111/j.1600-0714.1987.tb00677.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES